Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0081313 |
| Name | primary diffuse large B-cell lymphoma of the central nervous system |
| Definition | A diffuse large B-cell lymphoma arising from the central nervous system. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma diffuse large B-cell lymphoma primary diffuse large B-cell lymphoma of the central nervous system |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02203526 | Phase I | Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal doxorubicin + Temozolomide Dexamethasone + Etoposide + Ibrutinib + Isavuconazole + Methotrexate + Pegylated liposomal doxorubicin + Rituximab + Temozolomide Cytarabine + Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal doxorubicin + Rituximab + Temozolomide Cytarabine + Dexamethasone + Etoposide + Ibrutinib + Isavuconazole + Pegylated liposomal doxorubicin + Rituximab + Temozolomide | Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma | Recruiting | USA | 0 |
| NCT06931652 | Phase II | Epcoritamab-bysp + Lenalidomide + Rituximab | Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab (E-REVRI) | Not yet recruiting | FRA | 0 |
| NCT07137494 | Phase I | MB-CART19.1 | A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL) | Recruiting | USA | 0 |